Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Innoviva Inc (NASDAQ:INVA)

12.34
Delayed Data
As of Apr 29
 -0.01 / -0.08%
Today’s Change
6.36
Today|||52-Week Range
19.96
+17.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.4B

Company Description

Innoviva, Inc. is a biopharmaceutical company, with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. It engages in the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and central nervous system/pain. The company was founded by P. Roy Vagelos, Mathai Mammen and George M. Whitesides in November 1996 and is headquartered in South San Francisco, CA.

Contact Information

Innoviva, Inc.
901 Gateway Boulevard
South San Francisco California 94080
P:(650) 238-9600
Investor Relations:
(650) 808-4100

Employees

Shareholders

Other institutional50.63%
Mutual fund holders32.33%
Individual stakeholders1.12%

Top Executives

Michael W. AguiarPresident, Chief Executive Officer & Director
Eric d'EsparbesChief Financial Officer & Senior Vice President
Theodore L. WitekSenior Vice President-Clinical & Medical Affairs
George B. AbercrombieChief Commercial Officer & Senior Vice President
Mike E. FaermChief Business Officer & Senior Vice President